Rempex Pharmaceuticals, Inc.

Horizon Orphan LLC

Qpex Biopharma, Inc.

Mpex Pharmaceuticals, Inc.

Other

Raptor Pharmaceuticals Inc.

Melinta Therapeutics, Inc.

Olga Rodny

David C Griffith

Michael N Dudley

Scott J Hecker

Raja K Reddy

Tomasz W Glinka

Maxim Totrov

Gavin C Hirst

Keith A Bostian

Serge H Boyer

Mark William Surber

Brian Walter Eastman

Robert Higuchi

Ruslan Y Tsivkovski

David Mark Wallace

Chi Ching Mak

Chun Chow

Mike Dudley

David Griffith

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, β-lactamase inhibitors (BLIs).

Boronic acid derivatives and therapeutic uses thereof

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, &#x3b2;-lactamase inhibitors (BLIs).

The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided.

Topical use of levofloxacin for reducing lung inflammation

Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.

Aerosolized fluoroquinolones and uses thereof

The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.

Aerosol fluoroquinolone formulations for improved pharmacokinetics

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.

Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives

Method of treating or ameliorating a bacterial infection comprising administering a composition comprising a cyclic boronic acid ester compound in combination with a carbapenem antibacterial agent such as Biapenem, and the pharmacokinetics studies thereof are provided.

Cyclic boronic acid ester derivatives and therapeutic uses thereof

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.

Pharmaceutical compositions comprising cyclic boronic acid ester derivatives

Cyclic boronic acid ester derivatives and methods of making the same

Growing community of inventors

Mill Valley, CA, United States of America

Olga Rodny